LONDON Craig Venter's Celera Genomics is never afraid to court controversy, and a new agreement with the US journal
Ownership and control of intellectual property is the issue.
LONDON Craig Venter's Celera Genomics is never afraid to court controversy, and a new agreement with the US journal
Ownership and control of intellectual property is the issue.